{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:38Z","timestamp":1787021258052,"version":"build-2736575974"},"reference-count":13,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The synthetic retinoid bexarotene (BXT), used in the treatment of cutaneous T-cell lymphoma (CTCL), has been associated with central hypothyroidism due to suppression of thyrotropin (TSH) secretion and upregulation of peripheral thyroxine (T4) and triiodothyronine (T3) metabolism. We present a case of a 41-year-old man with CTCL who developed central hypothyroidism within 1 month of receiving BXT. He required sequential uptitration of levothyroxine (LT4) over 15 months, and free T4 (FT4) and total T3 levels were normalized by a daily regimen of LT4 600 mcg and liothyronine (LT3) 15 mcg. While almost all patients regain normal hypothalamic-pituitary-thyroid axis function after cessation of BXT, there are limited data regarding LT4 and LT3 dosing required to adequately treat central hypothyroidism in patients on BXT. Our patient required an LT4 dose approximately 2.8 times the calculated weight-based dose and LT3 supplementation, demonstrating a large LT4\/LT3 combination dose may be required to compensate for BXT-induced central hypothyroidism.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae041","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T17:10:39Z","timestamp":1709313039000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Treatment of Bexarotene-Induced Central Hypothyroidism"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-4186","authenticated-orcid":false,"given":"Marissa","family":"Tucci","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Tulane University School of Medicine , New Orleans, LA 70112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Galagan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tulane University School of Medicine , New Orleans, LA 70112 , USA"},{"name":"Southeast Louisiana Veterans Health Care System (SLVHCS) , New Orleans, LA 70112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-8768","authenticated-orcid":false,"given":"Dragana","family":"Lovre","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tulane University School of Medicine , New Orleans, LA 70112 , USA"},{"name":"Southeast Louisiana Veterans Health Care System (SLVHCS) , New Orleans, LA 70112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"14","key":"2024042306003491500_luae041-B1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor\u2013selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2024042306003491500_luae041-B2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3816\/CLM.2003.n.006","article-title":"Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma","volume":"3","author":"Sherman","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"7","key":"2024042306003491500_luae041-B3","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1210\/jc.2006-2822","article-title":"Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones","volume":"92","author":"Smit","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024042306003491500_luae041-B4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1089\/thy.2019.0256","article-title":"The levothyroxine absorption test: a four-year experience (2015-2018) at the mayo clinic","volume":"29","author":"Gonzales","year":"2019","journal-title":"Thyroid"},{"key":"2024042306003491500_luae041-B5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fendo.2020.00068","article-title":"Characteristics of serum thyroid hormones in different metabolic phenotypes of obesity","volume":"11","author":"Nie","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2024042306003491500_luae041-B6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1089\/thy.2020.0011","article-title":"Increased serum adipocyte fatty acid-binding protein levels are associated with decreased sensitivity to thyroid hormones in the euthyroid population","volume":"30","author":"Nie","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"2024042306003491500_luae041-B7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2337\/dc18-1410","article-title":"Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome","volume":"42","author":"Laclaustra","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"2024042306003491500_luae041-B8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/thy.2020.0720","article-title":"Evidence-based use of levothyroxine\/liothyronine combinations in treating hypothyroidism: a consensus document","volume":"31","author":"Jonklaas","year":"2021","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"2024042306003491500_luae041-B9","doi-asserted-by":"crossref","first-page":"A933","DOI":"10.1210\/jendso\/bvab048.1907","article-title":"High-dose thyroid hormone replacement in bexarotene-induced central hypothyroidism","volume":"5","author":"Mathews","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2024042306003491500_luae041-B10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"issue":"1","key":"2024042306003491500_luae041-B11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. Consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"2024042306003491500_luae041-B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cen.13975","article-title":"Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies","volume":"91","author":"Makita","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024042306003491500_luae041-B13","first-page":"32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur Endocrinol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/4\/luae041\/57300677\/luae041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/4\/luae041\/57300677\/luae041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T02:00:54Z","timestamp":1713837654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae041\/7637879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,22]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae041","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,22]]},"article-number":"luae041"}}